Award-winning campaign for Jorveza®.
Dr. Falk Pharma GmbH is a market leader in the fields of gastroenterology and hepatology. With Jorveza®, Dr. Falk has launched the first drug in Europe approved for the treatment of eosinophilic esophagitis.
Eosinophilic esophagitis, or EoE for short, is an allergy-related chronic inflammation of the esophagus that leads to severe swallowing difficulties. Our job was to get to the heart of the key symptoms of this rare disease in an eye-catching campaign.
With a key visual that is as simple as it is surprising, we illustrate how eosinophilic esophagitis feels to those affected. We received the gold medal in the “RX ads” category at the COMPRIX 2019.